AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Nano Biomedicine and Engineering Article
PDF (1.2 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

CIK Cell Therapy for Solid Tumor

Jingjing Zhang1, Yao Yang2, Hualin Fu1( )
Institute of Nano Biomedicine and Engineering, Department of Instrument Science and Engineering, Key Lab. for Thin Film and Microfabrication Technology of Ministry of Education, School of Electronic Information and Electronic Engineering, Shanghai Jiao Tong University, Shanghai 200240, China
School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China
Show Author Information

Abstract

In recent years, the clinical trials on applying cytokine induced killer (CIK) cells to solid tumor therapy have been launched worldwide. CIK cells are a heterogeneous subset of ex-vivo expanded T lymphocytes, they present a mixed T-NK phenotype and are endowed with a MHC-unrestricted antitumor activity, which have showed great advantages in clinical treatment compared with other adoptive immunity therapies, therefore, they are more and more widely used in adoptive immunotherapy of tumors. CIK cells can be used alone or in combination with surgery radiotherapy and chemotherapy for comprehensive treatment. In the present article, we keep a track of research progress both home and abroad, review the main functional characteristics of CIK cells, briefly introduce the source phenotype activation and amplification of the CIK cells, and summarize their targeting and anti-tumor mechanisms new techniques and methods and current status of international clinical trials from several aspects.

Keywords

CancerClinical TrialCytokine Induced Killer CellsCell Immunotherapy

References

[1]

Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. The Journal of experimental medicine 1991, 174(1): 139-149.
Crossref Google Scholar
[2]

Nishimura R, Baker J, Beilhack A, Zeiser R, Olson JA, Sega EI, Karimi M, Negrin RS: In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 2008, 112(6): 2563-2574.
Crossref Google Scholar
[3]

Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, Carnevale-Schianca F, Capaldi A, Geuna M, Casorzo L et al.: Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. International immunology 2008, 20(7): 841-848.
Crossref Google Scholar
[4]

Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, Introna M: Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011, 118(12): 3301-3310.
Crossref Google Scholar
[5]

Verneris MR, Kornacker M, Mailander V, Negrin RS: Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis. Cancer immunology, immunotherapy : CII 2000, 49(6): 335-345.
Crossref Google Scholar
[6]

Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS: Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004, 103(8): 3065-3072.
Crossref Google Scholar
[7]

Houchins JP, Yabe T, McSherry C, Bach FH: DNA sequence analysis of NKG2, a family of related cDNA clones encoding type Ⅱ integral membrane proteins on human natural killer cells. The Journal of experimental medicine 1991, 173(4): 1017-1020.
Crossref Google Scholar
[8]

Cosman D, Müllberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ: ULBPs, Novel MHC Class Ⅰ-Related Molecules, Bind to CMV Glycoprotein UL16 and Stimulate NK Cytotoxicity through the NKG2D Receptor. Immunity 2001, 14(2): 123-133.
Crossref Google Scholar
[9]

Lu PH, Negrin RS: A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. Journal of immunology (Baltimore, Md: 1950) 1994, 153(4): 1687-1696.
Crossref Google Scholar
[10]

Cohen SB, Woolley J, Bogunia-Kubik K, Natarajan P, Kotecha R, Belaramani L, Fallen PR, Perez-Cruz I, Madrigal JA: Macrophage colony stimulating factor (M-CSF) within cord blood sera may be partially responsible for the reduced proliferation of cord blood T cells. European cytokine network 2000, 11(4): 608-617.
Google Scholar
[11]

Robinson KL, Ayello J, Hughes R, van de Ven C, Issitt L, Kurtzberg J, Cairo MS: Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti-CD3, and IL-7. Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantation. Experimental hematology 2002, 30(3): 245-251.
Crossref Google Scholar
[12]

Gluckman E, Rocha V, Chevret S: Results of unrelated umbilical cord blood hematopoietic stem cell transplant. Transfusion clinique et biologique: Journal de la Societe francaise de transfusion sanguine 2001, 8(3): 146-154.
Crossref Google Scholar
[13]

Ende N, Lu S, Alcid MG, Chen R, Mack R: Pooled umbilical cord blood as a possible universal donor for marrow reconstitution and use in nuclear accidents. Life sciences 2001, 69(13): 1531-1539.
Crossref Google Scholar
[14]

Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M et al.: Phase Ⅰ clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. British journal of cancer 1999, 81(6): 1009-1016.
Crossref Google Scholar
[15]

Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A: Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematological oncology 2009, 27(3): 130-139.
Crossref Google Scholar
[16]

Wu C, Jiang J, Shi L, Xu N: Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer research 2008, 28(6b): 3997-4002.
Google Scholar
[17]

Weng DS, Zhou J, Zhou QM, Zhao M, Wang QJ, Huang LX, Li YQ, Chen SP, Wu PH, Xia JC: Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. Journal of immunotherapy (Hagerstown, Md : 1997) 2008, 31(1): 63-71.
Crossref Google Scholar
[18]

Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, Xu B, Wu J, Wang R, Xu J et al.: Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer research 2006, 26(3b): 2237-2242.
Google Scholar
[19]

Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, Feng YY, Fan ZP, Xu DP, Wang FS: Autologous cytokine-induced killer cell therapy in clinical trial phase Ⅰ is safe in patients with primary hepatocellular carcinoma. World journal of gastroenterology: WJG 2004, 10(8): 1146-1151.
Crossref Google Scholar
Nano Biomedicine and Engineering
Volume 6 Issue 2,
June 2014
Pages 60-66
DOI: 10.5101/nbe.v6i2.p60-66
Cite this article:
Zhang J, Yang Y, Fu H. CIK Cell Therapy for Solid Tumor. Nano Biomedicine and Engineering, 2014, 6(2): 60-66. https://doi.org/10.5101/nbe.v6i2.p60-66

354

Views

8

Downloads

0

Crossref

0

Scopus

Altmetrics
Received: 15 July 2014
Accepted: 15 August 2014
Published: 29 August 2014
© 2014 Jingjing Zhang, Yao Yang and Hualin Fu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Return